Brain Cancer Clinical Trials in Houston

Showing 41-60 of 207 trials

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

NCT02658279

The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab is an antibody that targets the immune system and activates it to stop cancer growth and/or kill cancer cells.

GliomaRecurrent Malignant Glioma

Memorial Sloan Kettering Cancer Center27 participantsStarted Jan 2016

Los Angeles, California, United States • San Francisco, California, United States • Miami, Florida, United States +13 more locations

RECRUITINGPhase 1/2< 1 mile

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

NCT06672575

The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.

Glioblastoma

M.D. Anderson Cancer Center45 participantsStarted Jan 2025

Houston, Texas, United States • Houston, Texas, United States

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

Brain Cancer Trials in Other Cities

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma

NG101m Adjuvant Therapy in Glioblastoma Patients

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Systematic Light Exposure in Pediatric Brain Tumor Survivors

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

DAY101 In Gliomas and Other Tumors

Other Conditions in Houston